MHC class II antigen presentation in melanoma: impact on immune recognition
Congressional District Code:
Biomedical Laboratory R&D
April 2021 -
FY 2021 Funding Amount:
Total Award Amount (all years):
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt:
Anti-tumor immune responses depend on T cell recognition of tumor antigens in the context of major histocompatibility complex (MHC) proteins to destroy tumors. While the MHC class I antigen presentation pathway in melanoma cells has a well-established role in immune-mediated destruction of tumors, the function of the MHC class II antigen presentation pathway in melanoma cells is not well understood. The goal of this proposal is to determine the function of MHC class II and the MHC class II antig...